Acrivon Therapeutics, Inc. · NASDAQ:ACRV
Acrivon Therapeutics — Technical Presentation (November 2026)
30 slides from Acrivon Therapeutics's technical presentation, Nov 10, 2026
Slide 1: Corporate R&D and KOL Event: Acrivon's New I&I Programs
CORPORATE R&D AND KOL EVENT ACRIVON’S NEW I&I PROGRAMS DIFFERENTIATED ASSETS IDENTIFIED WITH PROPRIETARY AP3 PLATFORM NOVEMBER 10, 2026 Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements Forward-looking statements Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or financial condition, business strategy
Slide 3: Today's agenda
Today’s agenda Today’s agenda Welcome Adam Levy, PhD, MBA, CFO Introduction and Overview Peter Blume-Jensen, MD, PhD, CEO EoE epidemiology and unmet need Arjan Bredenoord, MD, PhD EoE SOC (ACG Guidelines) Evan Dellon, MD, MPH Q&A and Discussion Mansoor Mirza, MD, CMO Adjourn Peter Blume-Jensen, MD,
Slide 4: Today's Participants
Today’s Participants Arjan Bredenoord, M.D., Ph.D. Professor, Gastroenterology and Hepatology, Amsterdam University Medical Center; Former President of the European Society of Eosinophilic Esophagitis EUREOS, a member of the UEG Scientific Committee Evan Dellon, M.D., M.P.H. Professor, Department of
Slide 5: Next-generation precision medicine powered by AP3
next-generation precision medicine powered by AP3 Drug P Acrivon Predictive Precision Proteomics (AP3) Generative AI-driven, proteomics-based rational drug design and informed clinical development AP3 enables an exact match between the disease-driving, dysregulated pathways with drug mechanism of ac
Slide 6: AP3 Generative AI phosphoproteomics platform
AP3 Generative AI phosphoproteomics platform Matching global drug effects with disease driving mechanisms Global MS Phosphoproteomic Profiling Biological Multimodal Data Patient responder prediction Indication Finding Drug combinations Target ID Drug Resistance Global PD markers Asset prioritization
Slide 7: Our Pipeline
our Pipeline Phase 3 Phase 2 Phase 1 Preclinical ACR-368 (CHK1/CHK2) Single-arm trial based on OncoSignature biomarker prediction Endometrial cancer AP3-identified tumor types ACR-525 (JAK1) ACR-368 single-agent · Breakthrough Device & Fast Track · Arm 1 ACR-2316 (WEE1/PKMYT1) Dose expansion AP3-ide
Slide 8: First AP3-based I&I program: Phase 2-ready oral selective JAK1 inhibitor ACR-525
FIRST AP3-based I&I PROGRAM: Phase 2-ready, oral, SELECTIVE jak1 INHIBITOR, ACR-525 (also known as AQ280) AP3 profiling Differentiated profile Phase 1 clinical data Extensive AP3 profiling against approved JAK inhibitors and dupilumab Desirable global phospho-proteomic pathway effects Highly JAK1-se
Slide 9: ACR-525 compares favorably to clinical benchmarks
ACR-525 compares favorably to clinical benchmarks Clinical comparators Disease-relevant cellular models AP3 phosphoproteomics Generative AI-enabled pathway insights ACR-525 Upadacitinib Filgotinib Abrocitinib Tofacitinib Brepocitinib Londamocitinib Y IL-4Rα antibody Tight, robust, structured data Du
Slide 10: AP3 analyses uncover TGFb pathway suppression by ACR-525
Generative AI-driven AP3 analyses uncover TGFb pathway suppression by Acr-525, a potential antifibrotic mechanism ACR-525-regulated pathway activity states Suppression of Non-SMAD TGFb pathway JAK1 STAT3 TGFβR1 P Fibrotic target genes ACR-525 Dupilumab Upadacitinib Brepocitinib Londamocitinib Contro
Slide 11: ACR-525 does not activate pro-apoptotic BAD signaling
ACR-525 does not activate pro-apoptotic BAD signaling, suggesting a potential safety advantage PAK1 BRAF BAD Apoptosis P S134 Th2 condition (TCR activation and IL4 stimulation) ACR-525 dupilumab Upadacitinib Brepocitinib Londamocitinib Control DMSO BAD_S134_M1 Log2 Intensity P Phosphorylation Differ
Slide 12: ACR-525 is potent and highly selective for JAK1
Molecule Relative potency (biochemical IC50) JAK1/JAK2 Relative potency (cellular IC50) JAK1/JAK2 (right panel) ACR-525 49× JAK1: 3.5 JAK2: 171 >120× IFNα ~24 GM-CSF >3,000 Abrocitinib 28× JAK1: 29.2 JAK2: 803 >90× IFNα ~34 GM-CSF >3,000 BMS-911543 0.01× JAK1: 75 JAK2: 1.1 0.40× IFNα ~1,300 GM-CSF ~
Slide 13: ACR-525 dose-dependently reduces Th2-relevant disease markers
ACR-525 dose-dependently reduces Th2-relevant disease markers in preclinical and clinical studies Log [ACR-525] (mM) Log [ACR-525] (mM) ACR-525 reduces the inflammation marker CXCL10 (Phase 1 MAD) ACR-525 reduces pSTAT3 in Th2 allergic inflammation in vivo mouse model ACR-525 reduces EoE Th2 inflamm
Slide 14: JAK1 plays a central role in EoE
Kleuskens et al. DDW 2026 JAK1 plays a central role in EoE Key cytokines IL-4 and IL-13 signal via JAK1-STAT6 Several critical Single Nucleotide Polymorphisms (SNPs) within the JAK-STAT signaling pathway in EoE JAK inhibitors are effective for atopic dermatitis Case reports show efficacy of JAK inhi
Slide 15: JAK1 is a key mediator of inflammatory signaling in EoE
JAK1 is a key mediator of inflammatory signaling in EoE EoE, an attractive first indication for ACR-525 IL-13 IL-4 IL-15 OSM IL-9 IL-5 TSLP Esophageal epithelium Th2 inflammation Eosinophils Mast cells APCs Stromal / epithelial cells TSLP IL-7Rα / CRLF2 JAK1 IL-4 γc / IL-4Rα JAK1 IL-13 IL-4Rα / IL-1
Slide 16: ACR-525 prevents IL-13 and OSM-induced epithelial barrier damage
ACR-525 Epithelium Th2 inflammation Eosinophils Mast cells APCs Stromal/ Epithelial cells dupilumab tezepelumab cendakimab ACR-525 prevents il-13 and OSM-induced epithelial barrier damage Broader activity than Dupilumab, which fails to prevent OSM damage Medium IL-13 DMSO + IL-13 ACR-525 + IL-13 Iso
Slide 17: Huge increase in EoE over the past years
Huge increase in EoE over the past 25 years Dellon and Hirano, Gastroenterology 2018
Slide 18: EoE – a rapidly growing patient population of unmet need
EoE – a rapidly growing patient population of unmet need Growth Metric US Estimate Prevalence in 2009 28.3/100,000 Prevalence in 2022 163.1/100,000 Total increase over 13 years +477% Average annual growth ~14.4% Equivalent growth every 5 years ~96% Multiplication over 13 years 5.8× Annual Incidence
Slide 19: EoE burden: symptoms and chronic therapy
EoE burden: symptoms and chronic therapy EoE leads to esophageal obstruction: inability to pass solid foods EoE leads to a profound loss in health-related quality of life EoE is chronic and leads to fibrostenosis Requires long-term treatment for symptom control and prevention of esophageal scarring
Slide 20: EoE treatment algorithm – ACG guidelines 2025
EoE treatment algorithm – ACG guidelines 2025 EoE diagnosis established Treat inflammation and assess for fibrostenosis in all patients Anti-inflammatory treatment Pharmacologic treatment Diet elimination treatment Shared decision-making PPI Topical steroids Empiric elimination Assess response Fibro
Slide 21: Unmet need in EoE – new treatments are still needed
Unmet need in EoE – new treatments are still needed First line therapies: Suboptimal responses (>50% may be non-responders) Adherence difficulties (twice daily dosing; restrictive diets) Concern for side effects Loss of response is frequently observed Biologics Currently position as “step-up” and se
Slide 22: Preclinical PKCθ program
Preclinical PKCθ program PKCθ plays critical role in T cell activation Key role in T-cell activation Induces NF-κB and AP-1 activation Strong evidence based on extensive preclinical studies Mouse colitis, allergic airway and human RA studies uncover key role of PKCθ in T cell-mediated inflammation S
Slide 23: Preclinical PKCθ program: ACR-525 + PKC-θi rational combination
Preclinical PKCθ program PKCθ plays critical role in T cell activation Selected primary studies: Sun, Nature 2000. Marsland, J Exp Med 2004. Nagahama, Gastroenterology 2008. Zanin-Zhorov, Science 2010. Kong, Nat Immunol 2011. ACR-525 + PKC-θi rational combination Cytokine receptors TCR / CD28 JAK1 P
Slide 24: ACR-525 is highly differentiated and compares favorably to approved JAK inhibitors
AP3 ACR-525 profiled H:H against 6 approved JAK inhibitors and dupilumab Broader indication potential JAK1-selectivity + distinct TGFβ pathway suppression Benchmark differentiation Selectivity, oral availability, and desirable pathway potency Safety-related profiling No pro-apoptotic BAD phosphoryla
Slide 25: Q&A and Discussion
Q&A and Discussion
Slide 26: Appendix
appendix
Slide 27: AP3 generative AI-driven phosphoproteomics profiling
AP3 generative AI-driven phosphoproteomics profiling global, cellular drug pathway effects and compound differentiation AP3 Generative AI-driven phosphoproteomics analytics Drug-regulated pathway perturbation Drug-regulated kinase activity Drug-regulated phosphosites Drug treatment LC-MS/MS profilin
Slide 28: The AP3 approach is modality and disease agnostic
Infectious, CNS, and other diseases Oncology Fibrotic and inflammatory Autoimmune DDR and Cell Cycle Therapeutic areas Therapeutic modalities Small molecule Bifunctional molecule Antibody ADC Oligo/RNA The AP3 Approach is modality and disease agnostic AP3 Oncology programs AP3 I&I programs
Slide 29: Preclinical PKCθ program: T cell activation
Preclinical PKCθ program PKCθ plays critical role in T cell activation Critical role in T-cell activation Supports NF-κB and AP-1 activation and cooperates with calcium/NFAT signaling. Effector–regulatory balance Convergence with JAK/STAT mediated Th2/Th17 pathways Strong rationale based on extensiv
Slide 30: Development opportunities: AP3-defined rational combinations with ACR-525
Development opportunities: AP3-DEFINED RATIONAL COMBINATIONS WITH ACR-525 ACR-525 + PKC-θi ACR-525 + IL-23i Cytokine receptors TCR / CD28 JAK1 PKCθ ACR- 525 PKCϴi STAT NF-κB / AP-1 Inflammatory T-cell function IL-23 Tremfya IFNγ / IL-6 IL-23R JAK2 / TYK2–STAT3 JAK1 ACR- 525 IL-23-responsive Th17 / I
Acrivon Therapeutics — Technical Presentation (November 2026) on 6ix